



PRESS RELEASE

Crucell Receives European Patent Covering PER.C6[®] for Vaccine Production

Leiden, The Netherlands, January 5, 2005 – Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) announced today that it has been granted a patent by the European Patent Office specifically relating to the use of its proprietary PER.C6[®] technology for the production of vaccines.

The patent (number: EP 1108787 B1) firmly protects the use of the PER.C6[®] technology for the production of all non-adenoviral viruses, including influenza viruses, for use in veterinary or human vaccines. Further, the patent quite broadly covers the production of any non-adenoviral virus on E1-immortalized cell lines.

This patent further strengthens Crucell's patent position in the emerging field of cell-based vaccines.

About Crucell

Crucell N.V. is a biotechnology company focused on developing vaccines and antibodies that prevent and treat infectious diseases, including Ebola, influenza, malaria, West Nile virus and rabies. The company's development programs include collaborations with Aventis Pasteur for influenza vaccines, the U.S. National Institutes of Health for Ebola and malaria vaccines, and GlaxoSmithKline (GSK), Walter Reed Army Institute of Research and New York University for a malaria vaccine. Crucell's products are based on its innovative PER.C6[®] technology, which offers a safer, more efficient way to produce biopharmaceuticals. The company licenses its PER.C6[®] technology to the biopharmaceutical industry on a mostly non-exclusive basis. Licensees and CMO partners include DSM Biologics, GSK, Centocor/J&J and Merck & Co., Inc. Crucell is headquartered in Leiden, The Netherlands, and is listed on the Euronext and NASDAQ stock exchanges (ticker symbol CRXL). For more information, please visit www.crucell.com.

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on February 27, 2004, and the section entitled "Risk Factors". The company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP).

For further information please contact:

Crucell N.V.

Elizabeth Goodwin
Director IR & Corp. Communications
Tel. +31 (0)71 524 8718
e.goodwin@crucell.com

For Crucell in the US:

Redington, Inc.
Thomas Redington
Tel. +1 212-926-1733
tredington@redingtoninc.com